Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy.
The genes encoding the BRCA1 and BRCA2 tumor suppressors are the most commonly mutated in human familial breast cancers. Both have separate roles in the maintenance of genomic stability through involvement in homologous recombination, an error-free process enabling cells to repair DNA double-strand breaks. We have previously shown that cre-mediated conditional deletion of Brca2 within the mouse small intestine sensitizes the tissue to DNA damage. Eventually, the tissue repopulates via stem cells in which recombination at the floxed Brca2 allele has not taken place. In this study, we have treated Brca2-deficient small intestine with a potent small-molecule inhibitor of poly(ADP-ribose) polymerase 1 (PARP1), an enzyme predominantly involved in the recognition of DNA single-strand breaks. Brca2 deficiency rendered otherwise normal cells exquisitely sensitive to PARP inhibition, resulting in very high levels of apoptosis as early as 6 hours after treatment, with evidence for repopulation of the tissue at 12 hours. Furthermore, the intestines of animals treated with serial injections of the inhibitor repopulated very rapidly in comparison with those from untreated mice. Our results represent the first in vivo demonstration that inhibition of PARP1 activity confers exquisite sensitivity to death in physiologically normal Brca2-deficient cells, suggesting that such a regimen may be extremely potent prophylactically in women heterozygous for the BRCA2 gene, as well as against established tumors lacking functional BRCA2.
Hay
Trevor
T
School of Bioscience, Cardiff University, Cardiff, United Kingdom.
Jenkins
Helen
H
Sansom
Owen J
OJ
Martin
Niall M B
NM
Smith
Graeme C M
GC
Clarke
Alan R
AR
D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D024682:BRCA2 Protein / Q000172:deficiency*; D001682:Biological Availability; D001943:Breast Neoplasms / Q000235:genetics / Q000517:prevention & control*; D004249:DNA Damage; D004791:Enzyme Inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology; D005464:Fluorobenzenes / Q000493:pharmacokinetics / Q000494:pharmacology; D017353:Gene Deletion; D024522:Genes, BRCA2; D007413:Intestinal Mucosa / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism / Q000502:physiology*; D007421:Intestine, Small / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism / Q000502:physiology*; D051379:Mice; D008822:Mice, Transgenic; D010793:Phthalazines / Q000493:pharmacokinetics / Q000494:pharmacology; D000067856:Poly(ADP-ribose) Polymerase Inhibitors
D024682:BRCA2 Protein; D004791:Enzyme Inhibitors; D005464:Fluorobenzenes; C506932:KU0058948; D010793:Phthalazines; D000067856:Poly(ADP-ribose) Polymerase Inhibitors